Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Robert, 2011, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, 364, 2517, 10.1056/NEJMoa1104621 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Schadendorf, 2015, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma, J Clin Oncol, 33, 1889, 10.1200/JCO.2014.56.2736 Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358 Weber, 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, J Clin Oncol, 30, 2691, 10.1200/JCO.2012.41.6750 Beck, 2006, Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4, J Clin Oncol, 24, 2283, 10.1200/JCO.2005.04.5716 Gupta, 2015, Systematic review: colitis associated with anti-CTLA-4 therapy, Aliment Pharmacol Ther, 42, 406, 10.1111/apt.13281 Marthey, 2016, Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease, J Crohns Colitis, 10, 395, 10.1093/ecco-jcc/jjv227 Abraham, 2009, Inflammatory bowel disease, N Engl J Med, 361, 2066, 10.1056/NEJMra0804647 Chassaing, 2011, The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases, Gastroenterology, 140, 1720, 10.1053/j.gastro.2011.01.054 Lepage, 2011, Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis, Gastroenterology, 141, 227, 10.1053/j.gastro.2011.04.011 Vétizou, 2015, Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota, Science, 350, 1079, 10.1126/science.aad1329 Sivan, 2015, Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy, Science, 350, 1084, 10.1126/science.aac4255 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624 Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N Engl J Med, 371, 2189, 10.1056/NEJMoa1406498 Seksik, 2003, Alterations of the dominant faecal bacterial groups in patients with Crohn’s disease of the colon, Gut, 52, 237, 10.1136/gut.52.2.237 Chen, 2009, Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues, Proc Natl Acad Sci USA, 106, 2729, 10.1073/pnas.0813175106 Read, 2006, Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo, J Immunol, 177, 4376, 10.4049/jimmunol.177.7.4376 Lukiw, 2016, Bacteroides fragilis lipopolysaccharide and inflammatory signaling in Alzheimer’s disease, Front Microbiol, 7, 1544., 10.3389/fmicb.2016.01544 Guigoz, 2008, The inflammatory status of old age can be nurtured from the intestinal environment, Curr Opin Clin Nutr Metab Care, 11, 13, 10.1097/MCO.0b013e3282f2bfdf Le Chatelier, 2013, Richness of human gut microbiome correlates with metabolic markers, Nature, 500, 541, 10.1038/nature12506 Sokol, 2008, Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, Proc Natl Acad Sci USA, 105, 16731, 10.1073/pnas.0804812105 Devillard, 2007, Metabolism of linoleic acid by human gut bacteria: different routes for biosynthesis of conjugated linoleic acid, J Bacteriol, 189, 2566, 10.1128/JB.01359-06 Mathewson, 2016, Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease, Nat Immunol, 17, 505, 10.1038/ni.3400 Smith, 2013, The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis, Science, 341, 569, 10.1126/science.1241165 Gray, 1988, A class of $K$-sample tests for comparing the cumulative incidence of a competing risk, Ann Statist, 16, 1141, 10.1214/aos/1176350951 Lin G, So Y, Johnston G, Analysing survival data with competing risks using SAS* software. Proc. SAS Glob. Forum 2012 Conference, Cary, NC. SAS Inst. Inc. 2012. Riley, 2001, ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement, J Immunol, 166, 4943, 10.4049/jimmunol.166.8.4943 Lotze, 1987, In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration, Cancer Res, 47, 2188 Dubin, 2016, Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis, Nat Commun, 7, 10391., 10.1038/ncomms10391 Maynard, 2012, Reciprocal interactions of the intestinal microbiota and immune system, Nature, 489, 231, 10.1038/nature11551 Cebula, 2013, Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota, Nature, 497, 258, 10.1038/nature12079 Png, 2010, Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria, Am J Gastroenterol, 105, 2420, 10.1038/ajg.2010.281 Hedin, 2014, Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn’s disease and their unaffected siblings, Gut, 63, 1578, 10.1136/gutjnl-2013-306226 Romano, 2015, Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients, Proc Natl Acad Sci USA, 112, 6140, 10.1073/pnas.1417320112 Fu, 2011, The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy, Cancer Res, 71, 5445, 10.1158/0008-5472.CAN-11-1138 Liakou, 2008, CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients, Proc Natl Acad Sci USA, 105, 14987, 10.1073/pnas.0806075105 Sim, 2014, IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients, J Clin Invest, 124, 99, 10.1172/JCI46266 Klatzmann, 2015, The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases, Nat Rev Immunol, 15, 283, 10.1038/nri3823 Chaput, 2013, Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome, Oncoimmunology, 2, e23080., 10.4161/onci.23080 Yu, 2015, Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes, Diabetes, 64, 2172, 10.2337/db14-1322 Hodi, 2016, Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial, Lancet Oncol, 17, 1558, 10.1016/S1470-2045(16)30366-7 Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 1270, 10.1056/NEJMc1509660